PMID- 20146105
OWN - NLM
STAT- MEDLINE
DCOM- 20110802
LR  - 20211020
IS  - 1559-131X (Electronic)
IS  - 1357-0560 (Linking)
VI  - 28
IP  - 1
DP  - 2011 Mar
TI  - Prognostic significance of telomerase activity and some tumor markers in 
      non-small cell lung cancer.
PG  - 322-30
LID - 10.1007/s12032-010-9444-0 [doi]
AB  - The prognosis of non small cell lung cancer (NSCLC) has remained disappointing 
      over the last decades even in localized stages. Numerous prognostic factors have 
      been investigated which might select patients for additional treatment. The 
      objective of the current study was to assess the prognostic significance of 
      telomerase activity, serum anti-p53 antibodies (anti-p53a), c-erbB-2 and CEA in 
      patients with NSCLC. The study included 60 patients with histological proven 
      NSCLC besides 60 controls (30 smokers and 30 nonsmokers). Patients were divided 
      into four stages according to their histopathology. All patients were subjected 
      to; determination of telomerase activity by telomeric repeat amplification 
      protocol (TRAP) assay in tumor tissue specimens and adjacent normal lung tissues, 
      also, determination of preoperative serum anti-p53a, c-erbB-2 and CEA. Telomerase 
      activity was detected in 40 of 60 (66.6%) of NSCLC tissue specimens using the 
      TRAP assay. As regard the stages, telomerase activity was positive in 5 of 15 
      patients (33.3%) with stage I NSCLC, in 11 of 20 patients (55%) with stage II 
      NSCLC, in 9 of 10 patients (90%) with stage III NSCLC and in all patients (100%) 
      with stage IV NSCLC. More cases of positive telomerase activity were observed in 
      the group with advanced disease and in the group with poorly differentiated 
      tumors. Telomerase activity was not detected in any normal lung tissue. The 
      concentrations of serum anti-p53a, c-erbB-2, CEA were significantly higher in 
      patients with NSCLC in comparison to the smoker and nonsmoker controls and their 
      levels increased according to the stage of disease. Logistic regression test 
      showed a relation between telomerase positivity and anti- p53a but no relation 
      with c-erbB2, CEA. Telomerase activity was detected in most of NSCLC tissues; it 
      was detected more frequently in advanced disease than early-stage disease. 
      Anti-p53, c-erbB-2 and CEA were significantly higher in patients with NSCLC than 
      controls and this increment was more evident in late stages of the disease. So, 
      these biological markers might be useful predictors of prognosis. They may be 
      helpful in defining groups of patients with NSCLC who could benefit from adjuvant 
      treatments, also these markers can be used as therapeutic targets.
FAU - Hashim, Maha
AU  - Hashim M
AD  - Biochemistry Department, National Research Centre, Cairo, Egypt.
FAU - Sayed, Magda
AU  - Sayed M
FAU - Samy, Nervana
AU  - Samy N
FAU - Elshazly, Salah
AU  - Elshazly S
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20100210
PL  - United States
TA  - Med Oncol
JT  - Medical oncology (Northwood, London, England)
JID - 9435512
RN  - 0 (Biomarkers, Tumor)
RN  - EC 2.7.7.49 (TERT protein, human)
RN  - EC 2.7.7.49 (Telomerase)
SB  - IM
MH  - Adenocarcinoma/*metabolism/pathology
MH  - Adult
MH  - Biomarkers, Tumor/*metabolism
MH  - Carcinoma, Non-Small-Cell Lung/*metabolism/pathology
MH  - Carcinoma, Squamous Cell/*metabolism/pathology
MH  - Case-Control Studies
MH  - Female
MH  - Humans
MH  - Lung/metabolism/pathology
MH  - Lung Neoplasms/*metabolism/pathology
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Telomerase/*metabolism
EDAT- 2010/02/11 06:00
MHDA- 2011/08/04 06:00
CRDT- 2010/02/11 06:00
PHST- 2010/01/27 00:00 [received]
PHST- 2010/01/29 00:00 [accepted]
PHST- 2010/02/11 06:00 [entrez]
PHST- 2010/02/11 06:00 [pubmed]
PHST- 2011/08/04 06:00 [medline]
AID - 10.1007/s12032-010-9444-0 [doi]
PST - ppublish
SO  - Med Oncol. 2011 Mar;28(1):322-30. doi: 10.1007/s12032-010-9444-0. Epub 2010 Feb 
      10.